On the 18th, Medipixel (CEO Song Gyo-seok), which focuses on heart problems diagnosis artificial intelligence (AI) solutions, signed a possible MOU with India’s IITPL, which manufactures cardiovascular imaging medical devices, for purchase price $4.5 million (roughly KRW 6 billion). revealed

The 2 firms announced that they’ve decided to strengthen their cooperative relationship to construct a robust medical ecosystem that encompasses each hardware (HW) and software (SW) in the sphere of cardiovascular interventional procedures.

Specifically, Medipixel plans to rapidly advance into the Indian medical device market, which is predicted to succeed in $561.4 billion by 2027 with a steep annual growth rate of about 5%. The corporate emphasized that the 2 firms will lead the settlement and business expansion of the AI ​​healthcare market in India by integrating HW and SW and providing solutions.

Meanwhile, following the recent FDA approval and US patent registration, Medipixel has tapped into global expansion by establishing a US corporation in Boston, a global bio and healthcare cluster. are concentrating on

After the fundamental contract, we plan to begin full-scale work to integrate HW and SW of the product. Locally optimized integrated solutions are supplied in the shape of a three-year license.

Song Gyo-seok, CEO of Medipixel, said, “From the start of our foundation, now we have been promoting product development and business with the goal of entering the worldwide market. Recently, MPXA products have been approved by the FDA, and we’re receiving continuous purchase inquiries,” he said. “Following our business partnership relationship with Philips, we are going to speed up our global expansion by solidifying a revenue model based on partnerships with global medical device manufacturers reminiscent of India’s IITPL.” said.

Reporter Juyoung Lee juyoung09@aitimes.com